Literature DB >> 23761272

Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls.

Kathryn L Terry1, Stalo Karageorgi, Yurii B Shvetsov, Melissa A Merritt, Galina Lurie, Pamela J Thompson, Michael E Carney, Rachel Palmieri Weber, Lucy Akushevich, Wei-Hsuan Lo-Ciganic, Kara Cushing-Haugen, Weiva Sieh, Kirsten Moysich, Jennifer A Doherty, Christina M Nagle, Andrew Berchuck, Celeste L Pearce, Malcolm Pike, Roberta B Ness, Penelope M Webb, Mary Anne Rossing, Joellen Schildkraut, Harvey Risch, Marc T Goodman.   

Abstract

Genital powder use has been associated with risk of epithelial ovarian cancer in some, but not all, epidemiologic investigations, possibly reflecting the carcinogenic effects of talc particles found in most of these products. Whether risk increases with number of genital powder applications and for all histologic types of ovarian cancer also remains uncertain. Therefore, we estimated the association between self-reported genital powder use and epithelial ovarian cancer risk in eight population-based case-control studies. Individual data from each study were collected and harmonized. Lifetime number of genital powder applications was estimated from duration and frequency of use. Pooled ORs were calculated using conditional logistic regression matched on study and age and adjusted for potential confounders. Subtype-specific risks were estimated according to tumor behavior and histology. 8,525 cases and 9,859 controls were included in the analyses. Genital powder use was associated with a modest increased risk of epithelial ovarian cancer [OR, 1.24; 95% confidence interval (CI), 1.15-1.33] relative to women who never used powder. Risk was elevated for invasive serous (OR, 1.20; 95% CI, 1.09-1.32), endometrioid (OR, 1.22; 95% CI, 1.04-1.43), and clear cell (OR, 1.24; 95% CI, 1.01-1.52) tumors, and for borderline serous tumors (OR, 1.46; 95% CI, 1.24-1.72). Among genital powder users, we observed no significant trend (P = 0.17) in risk with increasing number of lifetime applications (assessed in quartiles). We noted no increase in risk among women who only reported nongenital powder use. In summary, genital powder use is a modifiable exposure associated with small-to-moderate increases in risk of most histologic subtypes of epithelial ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23761272      PMCID: PMC3766843          DOI: 10.1158/1940-6207.CAPR-13-0037

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  38 in total

1.  Genital powder exposure and the risk of epithelial ovarian cancer.

Authors:  Karin A Rosenblatt; Noel S Weiss; Kara L Cushing-Haugen; Kristine G Wicklund; Mary Anne Rossing
Journal:  Cancer Causes Control       Date:  2011-03-10       Impact factor: 2.506

2.  Prospective study of talc use and ovarian cancer.

Authors:  D M Gertig; D J Hunter; D W Cramer; G A Colditz; F E Speizer; W C Willett; S E Hankinson
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  Perineal powder exposure and the risk of ovarian cancer.

Authors:  L S Cook; M L Kamb; N S Weiss
Journal:  Am J Epidemiol       Date:  1997-03-01       Impact factor: 4.897

Review 4.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

5.  Perineal talc exposure and subsequent epithelial ovarian cancer: a case-control study.

Authors:  C Wong; R E Hempling; M S Piver; N Natarajan; C J Mettlin
Journal:  Obstet Gynecol       Date:  1999-03       Impact factor: 7.661

6.  Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk.

Authors:  Marc T Goodman; Galina Lurie; Pamela J Thompson; Katharine E McDuffie; Michael E Carney
Journal:  Endocr Relat Cancer       Date:  2008-07-30       Impact factor: 5.678

7.  Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California.

Authors:  Paul K Mills; Deborah G Riordan; Rosemary D Cress; Heather A Young
Journal:  Int J Cancer       Date:  2004-11-10       Impact factor: 7.396

8.  Ovarian cancer risk factors in African-American and white women.

Authors:  Patricia G Moorman; Rachel T Palmieri; Lucy Akushevich; Andrew Berchuck; Joellen M Schildkraut
Journal:  Am J Epidemiol       Date:  2009-07-15       Impact factor: 4.897

9.  Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.

Authors:  Melissa A Merritt; Adèle C Green; Christina M Nagle; Penelope M Webb
Journal:  Int J Cancer       Date:  2008-01-01       Impact factor: 7.396

10.  Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.

Authors:  C Blake Gilks
Journal:  J Oncol       Date:  2009-12-30       Impact factor: 4.375

View more
  38 in total

1.  Ovarian Cancer in Women of African Ancestry (OCWAA) consortium: a resource of harmonized data from eight epidemiologic studies of African American and white women.

Authors:  Joellen M Schildkraut; Lauren C Peres; Traci N Bethea; Fabian Camacho; Deanna Chyn; Emily K Cloyd; Elisa V Bandera; Alicia Beeghly-Fadiel; Loren Lipworth; Charlotte E Joslin; Faith G Davis; Patricia G Moorman; Evan Myers; Heather M Ochs-Balcom; Veronica Wendy Setiawan; Malcolm C Pike; Anna H Wu; Lynn Rosenberg
Journal:  Cancer Causes Control       Date:  2019-06-24       Impact factor: 2.506

2.  High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.

Authors:  Lauren C Peres; Adrianne R Mallen; Mary K Townsend; Elizabeth M Poole; Britton Trabert; Naomi E Allen; Alan A Arslan; Laure Dossus; Renée T Fortner; Inger T Gram; Patricia Hartge; Annika Idahl; Rudolf Kaaks; Marina Kvaskoff; Anthony M Magliocco; Melissa A Merritt; J Ramón Quirós; Anne Tjonneland; Antonia Trichopoulou; Rosario Tumino; Carla H van Gils; Kala Visvanathan; Nicolas Wentzensen; Anne Zeleniuch-Jacquotte; Shelley S Tworoger
Journal:  Cancer Res       Date:  2019-08-28       Impact factor: 12.701

3.  Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study.

Authors:  Hyo K Park; Joellen M Schildkraut; Anthony J Alberg; Elisa V Bandera; Jill S Barnholtz-Sloan; Melissa Bondy; Sydnee Crankshaw; Ellen Funkhouser; Patricia G Moorman; Edward S Peters; Paul Terry; Frances Wang; Julie J Ruterbusch; Ann G Schwartz; Michele L Cote
Journal:  Cancer Causes Control       Date:  2018-09-29       Impact factor: 2.506

4.  Douching, Talc Use, and Risk of Ovarian Cancer.

Authors:  Nicole L Gonzalez; Katie M O'Brien; Aimee A D'Aloisio; Dale P Sandler; Clarice R Weinberg
Journal:  Epidemiology       Date:  2016-11       Impact factor: 4.822

5.  Body Powder and Ovarian Cancer Risk-What Is the Role of Recall Bias?

Authors:  Britton Trabert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-10       Impact factor: 4.254

6.  Association between Body Powder Use and Ovarian Cancer: The African American Cancer Epidemiology Study (AACES).

Authors:  Joellen M Schildkraut; Sarah E Abbott; Anthony J Alberg; Elisa V Bandera; Jill S Barnholtz-Sloan; Melissa L Bondy; Michele L Cote; Ellen Funkhouser; Lauren C Peres; Edward S Peters; Ann G Schwartz; Paul Terry; Sydnee Crankshaw; Fabian Camacho; Frances Wang; Patricia G Moorman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-12       Impact factor: 4.254

Review 7.  Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium.

Authors:  Rikki Cannioto; Michael J LaMonte; Harvey A Risch; Chi-Chen Hong; Lara E Sucheston-Campbell; Kevin H Eng; J Brian Szender; Jenny Chang-Claude; Barbara Schmalfeldt; Ruediger Klapdor; Emily Gower; Albina N Minlikeeva; Gary R Zirpoli; Elisa V Bandera; Andrew Berchuck; Daniel Cramer; Jennifer A Doherty; Robert P Edwards; Brooke L Fridley; Ellen L Goode; Marc T Goodman; Estrid Hogdall; Satoyo Hosono; Allan Jensen; Susan Jordan; Susanne K Kjaer; Keitaro Matsuo; Roberta B Ness; Catherine M Olsen; Sara H Olson; Celeste Leigh Pearce; Malcolm C Pike; Mary Anne Rossing; Elizabeth A Szamreta; Pamela J Thompson; Chiu-Chen Tseng; Robert A Vierkant; Penelope M Webb; Nicolas Wentzensen; Kristine G Wicklund; Stacey J Winham; Anna H Wu; Francesmary Modugno; Joellen M Schildkraut; Kathryn L Terry; Linda E Kelemen; Kirsten B Moysich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-06       Impact factor: 4.254

8.  Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer.

Authors:  Kristina A Williams; S Intidhar Labidi-Galy; Kathryn L Terry; Allison F Vitonis; William R Welch; Annekathryn Goodman; Daniel W Cramer
Journal:  Gynecol Oncol       Date:  2014-01-23       Impact factor: 5.482

Review 9.  Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies.

Authors:  Christina B Rasmussen; Susanne K Kjaer; Vanna Albieri; Elisa V Bandera; Jennifer A Doherty; Estrid Høgdall; Penelope M Webb; Susan J Jordan; Mary Anne Rossing; Kristine G Wicklund; Marc T Goodman; Francesmary Modugno; Kirsten B Moysich; Roberta B Ness; Robert P Edwards; Joellen M Schildkraut; Andrew Berchuck; Sara H Olson; Lambertus A Kiemeney; Leon F A G Massuger; Steven A Narod; Catherine M Phelan; Hoda Anton-Culver; Argyrios Ziogas; Anna H Wu; Celeste L Pearce; Harvey A Risch; Allan Jensen
Journal:  Am J Epidemiol       Date:  2016-12-09       Impact factor: 4.897

Review 10.  Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.

Authors:  Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.